Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs
NCT ID: NCT00477308
Last Updated: 2020-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
95 participants
INTERVENTIONAL
2006-01-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children
NCT01225406
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983
Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients
NCT00356616
Emtricitabine/Tenofovir Alafenamide as Salvage ART
NCT02556333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After the study, the patients were managed based on the physician's judgment using genotyping results. The 95 patients in HIV-NAT 013 are categorized into 3 groups.
1. No viral resistance
2. Low grade resistance with or without clinical/ immunological failure
3. High grade resistance with or without clinical/ immunological failure.
There are limited prospective studies evaluating outcome of decision regarding salvage therapy after genotyping results
There are also new mutations that are not considered major mutation that may affect treatment outcome
Knowledge learned from this study will benefit Thai children with NRTI resistance by helping pediatricians better choose salvage treatment options
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
salvage therapy
Children with drug resistance were treated using the drug resistant profile
salvage therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
salvage therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swiss Cohort
UNKNOWN
The HIV Netherlands Australia Thailand Research Collaboration
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kiat Ruxrungtham, MD
Role: PRINCIPAL_INVESTIGATOR
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Tawee Chotpitayasunondh, MD
Role: PRINCIPAL_INVESTIGATOR
Queen Sirikit National Institute of Child Health, Bangkok
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chulalongkorn Hospital
Bangkok, , Thailand
Queen Sirikit National Institute of Child Health, Bangkok
Bangkok, , Thailand
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J; HIV-NAT 013 Study Team. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017. Epub 2009 Aug 21.
Related Links
Access external resources that provide additional context or updates about the study.
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIV-NAT 013 phase II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.